{"id":"W2121847974","doi":"10.1016/s1470-2045(15)70127-0","title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":955,"is_retracted":false,"has_abstract":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Bevacizumab; FOLFIRI; Ramucirumab; Medicine; Oxaliplatin; Oncology; Internal medicine; Colorectal cancer; Second-line therapy; Placebo; Chemotherapy; Overall survival; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002070412,0.002038846,0.00483002,0.0006030865,0.0004173464,0.001317689,0.001087958,0.001863766,0.003193644],"category_scores_gemma":[0.001695952,0.001007077,0.002957509,0.0004703534,0.001025974,0.001545831,0.0004215138,0.003710777,0.0007649325],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000934109,"about_ca_system_score_gemma":0.0009033749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00114289,"about_ca_topic_score_gemma":0.002649689,"domain_scores_codex":[0.9991757,0.0004282208,0.00005232747,0.0001462486,0.00004481807,0.0001526881],"domain_scores_gemma":[0.9991936,0.0002245014,0.0001944329,0.0000759707,0.00004690429,0.0002645896],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.981985,0.004130179,0.0003976224,0.0003377922,0.0007898417,0.00002854925,0.00004986785,0.0002283368,0.001815134,0.00003342692,0.0002489949,0.009955158],"study_design_scores_gemma":[0.8600777,0.1354023,0.002375284,0.00002691849,0.0007393245,0.00004086699,0.00003224092,0.0004282811,0.0004730174,0.00006676002,0.0003147224,0.00002257684],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920056,0.004682973,0.0002975839,0.0003582068,0.000444338,0.0008280145,0.0003014934,0.0001018623,0.0009798459],"genre_scores_gemma":[0.9942497,0.001778046,0.0006662597,0.000438061,0.0003494186,0.0006369009,0.0003741067,0.00001609198,0.001491356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00483002,"threshold_uncertainty_score":0.01094949,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09086894514201639,"score_gpt":0.3537783983077336,"score_spread":0.2629094531657172,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}